Avalyn Pharma’s Howard Lazarus sells 13,300 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Avalyn Pharma Inc. Chief Medical Officer Howard Lazarus exercised options for 13,300 shares of common stock at $4.62 per share on November 17, 2026. He sold 13,300 shares that day in three reported transactions: 11,023 at a weighted-average price of $27.8001, 2,066 at $28.2722, and 211 at $29.2722 per share. The exercise and sales were made pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. The option record reported 257,198 underlying shares following exercise; the option expires January 24, 2034.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F5 | 13,300 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 13,300 | $4.62 | $61K |
| Sale | Common Stock F1, F2 | 11,023 | $27.8001 | $306K |
| Sale | Common Stock F1, F3 | 2,066 | $28.2722 | $58K |
| Sale | Common Stock F1, F4 | 211 | $29.2722 | $6K |
Footnotes (5)
- F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.11 to $28.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.11 to $29.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.13 to $29.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F5. 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
substantially equal monthly installments technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were the vesting terms for Howard Lazarus's AVLN option?
AI-generated analysis. How Rhea-AI works. Not financial advice.